Equity · Healthcare
TSHA
NASDAQTaysha Gene Therapies (TSHA)
The line runs 5.16 USD on 22 September through 4.38 USD on 9 November, on a scale from 3 to 6. Days the market did not trade hold the previous close, flat.
- Market cap
- 1.4B USD
- Revenue, year to Dec 2025
- 9.8M USD
- EPS, diluted, year to Dec 2025
- −0.34 USD
- 52-week range
- 3.50 USD – 7 USD
- Avg volume
- 325.7K
- Mentions, 30 days
- 1
as of Nov 9, 2026
Have Taysha Gene Therapies (TSHA) insiders bought or sold shares recently?
TSHA's newest Form 4 filing is dated 10 July 2026: none in the last 90 days.
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 10 Jul 2026 | Nagendran SukumarPresident and Head of R&D | Sell | 200,000 | 1.2M USD |
| 10 Apr 2026 | Nagendran SukumarPresident and Head of R&D | Sell | 200,000 | 892K USD |
| 04 Feb 2026 | Alam KamranCHIEF FINANCIAL OFFICER | Sell | 1,655 | 7K USD |
| 26 Jan 2026 | Alam KamranCHIEF FINANCIAL OFFICER | Sell | 23,849 | 110K USD |
| 26 Jan 2026 | Nagendran SukumarPresident and Head of R&D | Sell | 26,918 | 124K USD |
| 26 Jan 2026 | Nolan Sean P.Chief Executive Officer | Sell | 41,312 | 190K USD |
| 23 Jan 2026 | Alam KamranCHIEF FINANCIAL OFFICER | Sell | 78,968 | 375K USD |
| 23 Jan 2026 | Nagendran SukumarPresident and Head of R&D | Sell | 89,132 | 423K USD |
| 23 Jan 2026 | Nolan Sean P.Chief Executive Officer | Sell | 136,789 | 650K USD |
| 12 Jan 2026 | Nagendran SukumarPresident and Head of R&D | Sell | 200,000 | 942K USD |
| 01 Dec 2025 | Nagendran SukumarPresident and Head of R&D | Sell | 260,047 | 1.2M USD |
| 28 Nov 2025 | Nagendran SukumarPresident and Head of R&D | Sell | 110,125 | 523K USD |
| Sold | 12 open-market sales | 1,368,795 | $6.66M |
11 other filings: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 01 Jun 2026 | Donenberg Phillip B.Director | Award | 21,335 | |
| 01 Jun 2026 | Long Alison SDirector | Award | 21,335 | |
| 01 Jun 2026 | Sepp-Lorenzino LauraDirector | Award | 21,335 | |
| 01 Jun 2026 | Stalfort John A IIIDirector | Award | 21,335 | |
| 10 Apr 2026 | Nagendran SukumarPresident and Head of R&D | Option exercise | 19,021 | 33K USD |
| 12 Jan 2026 | Alam KamranCHIEF FINANCIAL OFFICER | Award | 359,000 | |
| 12 Jan 2026 | Nagendran SukumarPresident and Head of R&D | Option exercise | 200,000 | 229K USD |
| 12 Jan 2026 | Nagendran SukumarPresident and Head of R&D | Award | 427,000 | |
| 12 Jan 2026 | Nolan Sean P.Chief Executive Officer | Award | 1,008,000 | |
| 01 Dec 2025 | Nagendran SukumarPresident and Head of R&D | Option exercise | 260,047 | 445K USD |
| 28 Nov 2025 | Nagendran SukumarPresident and Head of R&D | Option exercise | 110,125 | 117K USD |
Which funds hold Taysha Gene Therapies (TSHA)?
7 of the 45 institutional funds we track reported a Taysha Gene Therapies position for the quarter ended 30 Jun 2026 — a combined 85.9M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| D. E. Shaw & Co. | Held (±25%) | 4,398,652 | 30.0M USD | −0.6% |
| Baker Bros. Advisors | Held (±25%) | 4,004,756 | 27.3M USD | |
| Millennium Management | Trimmed | 2,126,838 | 14.5M USD | −35.2% |
| Citadel Advisors | Added | 1,535,287 | 10.5M USD | +273.4% |
| Two Sigma Investments | Trimmed | 234,716 | 1.6M USD | −68.4% |
| Balyasny Asset Management | Added | 189,332 | 1.3M USD | +128.1% |
| AQR Capital Management | Trimmed | 128,764 | 877K USD | −27.4% |
| Point72 Asset Management | Exited | |||
| Renaissance Technologies | Exited | |||
| Tudor Investment Corp | Exited |
What has been filed or recorded for Taysha Gene Therapies (TSHA)?
The filings we hold for Taysha Gene Therapies, newest first: 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Jun 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.13 USD | |
| 30 Jun 2026 | Financials | Total assets | 470.4M USD | at period end |
| 30 Jun 2026 | Financials | Total equity | 387.3M USD | at period end |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.12 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −0.34 USD | Revenue $10M |
| 31 Dec 2025 | Financials | Revenue | 9.8M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −109.0M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −0.34 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.09 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.09 USD | Revenue $2M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.08 USD | Revenue $2M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −0.36 USD | Revenue $8M |
| 30 Sep 2024 | Quarterly earnings | Q3 2024 reported | EPS −0.10 USD | Revenue $2M |
What is Reddit saying about Taysha Gene Therapies (TSHA)?
Reddit mentioned TSHA 1 times in the 30 days to 10 November 2026, in 1 of the communities we track. All of them were scored for sentiment: 100% read bullish, 0% bearish and 0% neither. Reddit data updated 10 November 2026.
30-day window, Method
How do Reddit mentions of Taysha Gene Therapies (TSHA) compare with its price?
Share ↗
Which subreddits are talking about Taysha Gene Therapies (TSHA)?
30 days
| Community | Share | Mentions | Net sentiment |
|---|---|---|---|
| r/stocks | 100% | 1 | +0.33 |
What do people ask about Taysha Gene Therapies (TSHA)?
What did Taysha Gene Therapies shares close at?4.38
Taysha Gene Therapies closed at 4.38 USD on 9 Nov 2026, up 0.92% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Taysha Gene Therapies’ market cap?1.4B
Taysha Gene Therapies is worth 1.4B USD by market value as of 9 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Taysha Gene Therapies’ revenue?9.8M
Taysha Gene Therapies reported revenue of 9.8M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Taysha Gene Therapies insiders bought or sold shares recently?
No Taysha Gene Therapies insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 10 Jul 2026 (SEC Form 4). See Insiders
Which funds own Taysha Gene Therapies?7 of 45
7 of the 45 funds we track reported a Taysha Gene Therapies position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were D. E. Shaw & Co., Baker Bros. Advisors and Millennium Management. See Funds
When did Taysha Gene Therapies last report earnings?−0.13
Taysha Gene Therapies last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −0.13 USD; no next date is announced in SEC filings yet. See Filings
What is Reddit saying about Taysha Gene Therapies?1 mentions
Taysha Gene Therapies was mentioned 1 times in the last 7 days across the finance subreddits we track, and 1 times over the trailing 30 days. Of the 1 mentions scored for sentiment, 100% read bullish and 0% bearish. That is a social signal, not investment advice. See Reddit
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- RedditReddit ingest across the tracked finance subreddits
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings